MING-LUNG Yu

Prof. Dr. MING-LUNG Yu

Hepatobiliary Division, Department of Medicine, Kaohsiung Medical University Hospital
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Gut
Verified
Journal Article
Closed access
PDF file
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
CDChia-Yen Dai
Chia-Yen Dai
JHJee-Fu Huang
Jee-Fu Huang
NHNai-Jen Hou
Nai-Jen Hou
LLL.-P. Lee
L.-P. Lee
WCWan-Long Chuang
Wan-Long Chuang
Background: The recommended treatment for patients infected with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks. Aim: To assess whether a shorter 16-week treatment is as effective as a standard 24-week treatment. Methods: Patients with HCV2 infection were randomised in a 1:2 ratio to either 16 weeks (n = 50) or 24 weeks (n = 100) of treatment with peginterferon α-2a (180 μg/week) and weight-based ribavirin 1000–1200 mg/day, with a 24-week follow-up period. A rapid virological response (RVR) was defined as seronegative for HCV RNA at 4 weeks of treatment, and the primary end point, sustained virological response (SVR), as seronegative for HCV RNA at the 24-week follow-up. Results: The rate of RVR and SVR was 86% (43/50, 95% confidence interval (CI) 76% to 96%) and 94% (47/50, CI 87% to 100%), respectively, in the 16-week group, which was comparable to 87% (87/100, CI 80% to 94%) and 95% (95/100, CI 91% to 99%) in the 24-week group. Patients with RVR had a significantly higher SVR rate than patients without RVR in both 16-week (100% vs 57%, p = 0.015) and 24-week groups (98% vs 77%, p = 0.002). Multivariate analysis showed that RVR and age were independent factors associated with SVR. Both treatment arms were equally well tolerated. The incidence of alopecia was significantly higher in the 24-week group (49%) than in the 16-week group (20%, p = 0.001). Conclusion: 16 weeks and 24 weeks of peginterferon treatment with weight-based ribavirin at a dose of 1000–1200 mg/day provided equal efficacy in patients with HCV2 who achieved RVR at 4 weeks.

28 May 2008 in Hepatology
Verified
Journal Article
Open access
PDF file
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
CDChia-Yen Dai
Chia-Yen Dai
JHJee-Fu Huang
Jee-Fu Huang
CCChang-Fu Chiu
Chang-Fu Chiu
YYYi-Hsin Yang
Yi-Hsin Yang
WCWan-Long Chuang
Wan-Long Chuang
Recommended treatment for hepatitis C virus genotype 1 (HCV-1) patients is peginterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as effective as standard treatment in HCV-1 patients with a rapid virological response (RVR; seronegative for hepatitis C virus [HCV] RNA at 4 weeks). Two hundred HCV-1 patients were randomized (1:1) to either 24 or 48 weeks of peginterferon-alpha-2a (180 μg/week) and ribavirin (1000–1200 mg/day) with a 24-week follow-up. The primary endpoint was a sustained virological response (SVR; seronegative for HCV RNA at 24-week follow-up). Overall, the 48-week arm had a significantly higher SVR rate (79%) than the 24-week arm (59%, P = 0.002). For 87 (43.5%) patients with an RVR, the 24-week arm had a lower SVR rate [88.9%; 95% confidence interval (CI): 80%–98%] than the 48-week arm (100%, P = 0.056). For 52 patients with low baseline viremia (<400,000 IU/mL) and an RVR, the 24-week arm had rates (CI) of relapse and SVR of 3.6% (−3%–11%) and 96.4% (89%–103%), respectively, which were comparable to those of the 48-week arm (0% and 100%) with difference (CI) of 3.6% (−7.2%–6.6%) and −3.6% (−14.3% to −0.6%), respectively. Multivariate analysis in all patients showed that RVR was the strongest independent factor associated with an SVR, followed by treatment duration, mean weight–based exposure of ribavirin, and baseline viral load. Conclusion: HCV-1 patients derive a significantly better SVR from 48 weeks versus 24 weeks of peginterferon/ribavirin even if they attain an RVR. Both 24 and 48 weeks of therapy can achieve high SVR rates (>96%) in HCV-1 patients with low viral loads and an RVR.

23 March 2009 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
WCWan‐Long Chuang
Wan‐Long Chuang

29 April 2016 in Hepatology International
Verified
Journal Article
Open access
PDF file
MOMasao Omata
Masao Omata
Tatsuo KandaTatsuo Kanda
Tatsuo Kanda
LWLai Wei
Lai Wei
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
WCWang-Long Chuang
Wang-Long Chuang
SSShiv Kumar Sarin
Shiv Kumar Sarin
The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the “APASL consensus statements and recommendation on management of hepatitis C” in March, 2015, in order to revise “APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409–435, 2012)”. The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.

1 December 2016 in Cancer Cell
Verified
Journal Article
Closed access
SNShigeki Nakagawa
Shigeki Nakagawa
LWLan Wei
Lan Wei
WSWon Min Song
Won Min Song
THTakaaki Higashi
Takaaki Higashi
SGSarani Ghoshal
Sarani Ghoshal
YHYujin Hoshida
Yujin Hoshida

1 March 2018 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MMMarcus M Mücke
Marcus M Mücke
LBLisa I Backus
Lisa I Backus
VMVictoria Therese Mücke
Victoria Therese Mücke
NCNicola Coppola
Nicola Coppola
CPCarmen M Preda
Carmen M Preda
JVJohannes Vermehren
Johannes Vermehren